Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 8.1%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s share price traded up 8.1% during mid-day trading on Tuesday . The company traded as high as $14.06 and last traded at $14.06. 150,280 shares traded hands during trading, a decline of 57% from the average session volume of 351,384 shares. The stock had previously closed at $13.01.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Canaccord Genuity Group upgraded Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. BMO Capital Markets cut their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. Morgan Stanley cut their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Finally, Wedbush reiterated an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.14.

Y-mAbs Therapeutics Trading Up 3.2 %

The firm has a fifty day moving average of $12.80 and a two-hundred day moving average of $13.49. The company has a market cap of $614.36 million, a PE ratio of -27.69 and a beta of 0.70.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.08). The firm had revenue of $22.80 million during the quarter, compared to analysts’ expectations of $23.09 million. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. During the same period last year, the business posted ($0.14) EPS. Sell-side analysts expect that Y-mAbs Therapeutics, Inc. will post -0.57 EPS for the current fiscal year.

Insider Activity

In other news, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the sale, the chief operating officer now owns 30,600 shares in the company, valued at approximately $449,514. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the sale, the chief operating officer now owns 30,600 shares in the company, valued at approximately $449,514. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the sale, the insider now directly owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. The disclosure for this sale can be found here. In the last 90 days, insiders sold 100,000 shares of company stock worth $1,338,100. 21.50% of the stock is currently owned by insiders.

Institutional Trading of Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC boosted its stake in shares of Y-mAbs Therapeutics by 23.8% during the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares during the period. Squarepoint Ops LLC boosted its stake in shares of Y-mAbs Therapeutics by 143.4% during the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after purchasing an additional 74,452 shares during the period. XTX Topco Ltd purchased a new stake in shares of Y-mAbs Therapeutics during the second quarter valued at approximately $297,000. Dimensional Fund Advisors LP boosted its stake in shares of Y-mAbs Therapeutics by 15.7% during the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after purchasing an additional 65,732 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Y-mAbs Therapeutics by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock valued at $993,000 after purchasing an additional 2,760 shares during the period. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.